The stock of Biomerica Inc (BMRA) has seen a -12.58% decrease in the past week, with a 0.23% gain in the past month, and a -30.02% decrease in the past quarter. The volatility ratio for the week is 8.09%, and the volatility levels for the past 30 days are at 11.03% for BMRA. The simple moving average for the last 20 days is -11.80% for BMRA stock, with a simple moving average of -45.48% for the last 200 days.
Is It Worth Investing in Biomerica Inc (NASDAQ: BMRA) Right Now?
Additionally, the 36-month beta value for BMRA is -1.15. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BMRA is 15.61M and currently, short sellers hold a 3.60% ratio of that float. The average trading volume of BMRA on November 21, 2024 was 440.51K shares.
BMRA) stock’s latest price update
The stock price of Biomerica Inc (NASDAQ: BMRA) has plunged by -5.12 when compared to previous closing price of 0.32, but the company has seen a -12.58% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-21 that IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ: BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (“GERD”), Crohn’s Disease, and Ulcerative Colitis using its proprietary inFoods® Technology. These patents apply to countries under the European Patent Organization (“EPO”), including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations within the EPO.
Analysts’ Opinion of BMRA
Many brokerage firms have already submitted their reports for BMRA stocks, with Colliers Securities repeating the rating for BMRA by listing it as a “Buy.” The predicted price for BMRA in the upcoming period, according to Colliers Securities is $13 based on the research report published on November 10, 2020 of the previous year 2020.
B. Riley FBR Inc., on the other hand, stated in their research note that they expect to see BMRA reach a price target of $7.50. The rating they have provided for BMRA stocks is “Buy” according to the report published on January 04th, 2018.
BMRA Trading at -7.63% from the 50-Day Moving Average
After a stumble in the market that brought BMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.55% of loss for the given period.
Volatility was left at 11.03%, however, over the last 30 days, the volatility rate increased by 8.09%, as shares surge +12.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.31% upper at present.
During the last 5 trading sessions, BMRA fell by -5.26%, which changed the moving average for the period of 200-days by -61.35% in comparison to the 20-day moving average, which settled at $0.3502. In addition, Biomerica Inc saw -75.38% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BMRA
Current profitability levels for the company are sitting at:
- -1.18 for the present operating margin
- 0.09 for the gross margin
The net margin for Biomerica Inc stands at -1.12. The total capital return value is set at -1.14. Equity return is now at value -76.48, with -58.44 for asset returns.
Based on Biomerica Inc (BMRA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -15.06.
Currently, EBITDA for the company is -5.99 million with net debt to EBITDA at 0.35. When we switch over and look at the enterprise to sales, we see a ratio of 0.56. The receivables turnover for the company is 3.55for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.00.
Conclusion
In conclusion, Biomerica Inc (BMRA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
